Figure: Biomieux received 510 (k) Authorization from FDA for its Vitek® Compact Pro (photo with kind permission of Biomieux)
Every year, 11 million people around the world die of sepsis, of which 1.3 million are caused by bacteria resistant to antibiotics. Antimicrobial resistance (RAM) remains a serious problem, making it difficult to detect resistant pathogens. It is essential that healthcare professionals obtain accurate identification and faster results of the sensitivity tests to antibiotics (PSA), which allowed the patient in time and adequate intervention in time and adequate intervention in the patient. Now the innovative tests of microorganism identification (ID) and antibiotic sensitivity (PSA) can benefit clinical laboratories that help to diagnose infectious diseases and fight RAM.
Vitek® Compact Pro de Biomieux (Marcy L’lile, France) combines the most advanced diagnostic technology with recognized benefits of its predecessor Vitek® 2 Compact. With advanced ergonomic design and simplified workflow, it improves user experience and general efficiency, as the laboratory technician devotes less time to loading and processing of samples. It offers one of the most effective workflows, faster routine ID/PSA results and microbiological experience to get accurate and reliable diagnostic information.
Ideal for small and medium laboratories, Vitek® Compact Pro also allows laboratories that are in the transition of manual work streams to benefit from automation. Biomieux received an authorization of 510 (K) from food and drug administration (FDA) for Vitek® Compact Pro. The commercial launch of Vitek® Compact Pro is originally planned in selected countries, followed by a global launch since the second quarter of 2025.
For decades, biomieux has been a leader in microbiology innovation. With the introduction of Vitek® Compact Pro continues this trajectory and satisfy the specific needs of our clients, support laboratories with simplified and more efficient workflows and the most advanced technology for optimizing their experience, said Jennifer Zinn, executive vice president for clinical operations. “Through the continuous expansion of our Vitek® Solutions Biomieux portfolio, it continues to strengthen our comprehensive AMS/AMS offer and strengthens our commitment to provide the latest ID/PSA systems for medical and laboratory experts from around the world.”
As a leader in the fight against RAM, Biomieux is constantly developing and renewing its key diagnostic solutions, added Céline Roger-Dalbert, a powerful vice president for research and development. “Vitek® Compact Pro offers fast, accurate and reproducible results comparable to the results of the Vitek® 2 and Vitek® 2 compact results.
(Tagstotranslate) Reports of Clinical Lip of the Day
